Janux Reports Q3 Results, Plans JANX011 Data
The San Diego biotech reported third-quarter 2026 financials and scheduled initial clinical data for November 9.
San Diego Biotech News
Biotech in San Diego runs on drug development, clinical trials, gene therapy and the funding and deals that move companies forward, and coverage here follows all of it. Reporting takes in research breakthroughs, regulatory milestones and the business of the region's life sciences companies.
Recent news
November 3, 2026
BlossomHill Joins Guggenheim Healthcare ConferenceThe San Diego biopharmaceutical company will present at the event and host a fireside chat on November 10, 2026.
October 26, 2026
San Diego Firm Expands Cancer Treatment TrialsRakuten Medical advances Phase 3 clinical trials for its photoimmunotherapy platform.
October 14, 2026
Adagene CEO Will Lead Conference Chat October 15Peter Luo of San Diego-based Adagene will discuss clinical programs at an upcoming biotech industry conference.
October 12, 2026
Haynes Boone Opened New San Diego OfficeThe law firm expanded its California presence to support life sciences and technology clients in San Diego.
October 12, 2026
Oncolytics Biotech Secured New Immunotherapy PatentsThe San Diego-based firm has obtained international patent protection for its cancer-fighting agent, pelareorep.
October 12, 2026
Fate Therapeutics Appointed New Commercial LeaderJamie Harrell has joined the San Diego-based firm to lead commercial strategies for its autoimmune and oncology programs.
October 9, 2026
San Diego Biotech Iambic Therapeutics Filed for IPOThe company seeks to raise $135 million through an offering of 9.4 million shares.
October 7, 2026
Byondis Will Present ADC Research in San DiegoThe company will detail its novel steric masking platform and clinical progress at the upcoming World ADC conference.
October 5, 2026
Iambic Therapeutics Submitted FDA Filing for Cancer DrugThe San Diego biotech company has moved its AI-designed KIF18A inhibitor into the federal regulatory process.
September 22, 2026
San Diego Biotech Iambic Therapeutics Filed for IPOThe San Diego-based drug discovery firm has moved to go public following a recent partnership deal.
Regular subjects here include trial readouts and what they measured, gene editing and genomics studies, biotech IPOs and venture rounds, and acquisitions of local drug developers. Coverage runs across the city and into the communities around it wherever a research campus or lab story crosses the line. Trial design and endpoints get as much attention as the headline result, since the two are often conflated. Financing conditions and the pace of licensing deals determine how many companies reach the next clinical stage.